City University of New York (CUNY)

CUNY Academic Works
Publications and Research

City College of New York

2013

Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431
human epidermoid carcinoma cells and targets β-catenin
-catenin
Niharika Nath
CUNY City College

Xiaoping Liu
SUNY Stony Brook

Lloydine Jacobs
CUNY City College

Khosrow Kashfi
CUNY City College

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/cc_pubs/419
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Drug Design, Development and Therapy

Dovepress
open access to scientific and medical research

ORIGNAL RESEARCH

Open Access Full Text Article

Flurbiprofen benzyl nitrate (NBS-242) inhibits
the growth of A-431 human epidermoid
carcinoma cells and targets β-catenin
This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
8 May 2013
Number of times this article has been viewed

Niharika Nath 1,2
Xiaoping Liu 3
Lloydine Jacobs 1
Khosrow Kashfi 1,3
Department of Physiology,
Pharmacology, and Neuroscience,
Sophie Davis School of Biomedical
Education, City University of
New York Medical School, New
York, NY, USA; 2Department of
Life Sciences, New York Institute
of Technology, New York, NY, USA;
3
Division of Cancer Prevention,
Department of Medicine, Stony
Brook University, Stony Brook,
NY, USA
1

Background: The Wnt/β-catenin/T cell factor (TCF) signaling pathway is important in the
development of nonmelanoma skin cancers (NMSCs). Nitric-oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are chemopreventive agents consisting of a traditional NSAID
attached to an NO-releasing moiety through a chemical spacer. Previously we showed that an
aromatic spacer enhanced the potency of a particular NO-NSAID compared to an aliphatic spacer.
Methods: We synthesized an NO-releasing NSAID with an aromatic spacer (flurbiprofen benzyl
nitrate, NBS-242), and using the human skin cancer cell line A-431, we evaluated its effects on
cell kinetics, Wnt/β-catenin, cyclin D1, and caspase-3.
Results: NBS-242 inhibited the growth of A-431 cancer cells, being ∼15-fold more potent than
flurbiprofen and up to 5-fold more potent than NO-flurbiprofen with an aliphatic spacer, the half
maximal inhibitory concentrations (IC50) for growth inhibition being 60 ± 4 µM, 320 ± 20 µM,
and 880 ± 65 µM for NBS-242, NO-flurbiprofen, and flurbiprofen, respectively. This effect
was associated with inhibition of proliferation, accumulation of cells in the G0/G1 phase of the
cell cycle, and an increase in apoptotic cell population. NBS-242 cleaved β-catenin both in
the cytoplasm and the nucleus of A-431 cells. NBS-242 activated caspase-3 whose activation
was reflected in the cleavage of procaspase-3. To test the functional consequence of β-catenin
cleavage, we determined the expression of cyclin D1, a Wnt-response gene. NBS-242 reduced
cyclin D1 levels in a concentration dependent manner.
Conclusion: These findings establish a strong inhibitory effect of NBS-242 in A-431 human
epidermoid carcinoma cells. NBS-242 modulates parameters that are important in determining
cellular mass.
Keywords: flurbiprofen, nitric oxide, β-catenin, chemoprevention, skin cancer
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In the USA, nonmelanoma skin cancers (NMSCs) are increasing by about one million
new cases annually.1 The Wnt/β-catenin/T cell factor (TCF) signaling pathway has
been shown to be important in the development of many cancers including colon,
prostate, leukemia, and others. The Wnt/β-catenin pathways are also implicated in the
development of malignancy in NMSCs such as squamous cell carcinoma (SCC) of the
skin2,3 and basal cell carcinoma (BCC).4 Mouse models of induced skin tumors have
provided evidence of constitutive activation of β-catenin/TCF signaling.5 β-catenin is a
multifunctional protein that controls a number of cell activities, both at the membrane
and the nuclear level. In the nucleus, β-catenin interacts with the TCF family of
transcription factors. Elevated β-catenin/TCF-4 signaling is correlated with activation
of its downstream target cyclin D1 and accelerated entry from the G1 phase into the
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S phase of the cell cycle. The upregulation of cyclin D1 is
generally accepted as the basis for β-catenin’s proliferative
and oncogenic effect.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
considered to be the prototypical cancer chemopreventive
agents. 6 A number of randomized, double-blind trials
of aspirin against colorectal adenomas have established
their chemopreventive effect.7–9 Recently, Rothwell et al10
reported that even daily use of low dose aspirin resulted in
reductions in cancer incidence and mortality. Moreover,
they also reported that aspirin prevented distant metastasis.11
For skin cancer, NSAIDs have been shown to have a
protective effect against SCC and BCC.12 Interestingly,
the data suggested that a shorter duration of use offered
a better protective effect than a longer duration of use.
Recently, it was shown that celecoxib, an NSAID which
selectively inhibits the enzyme cyclo-oxygenase-2, may be
effective for prevention of SCCs and BCCs in individuals
who have extensive actinic damage and are at high risk
for development of nonmelanoma skin cancers.13 A recent
study concluded that long-term use (.5 years) of NSAIDs,
especially aspirin, was associated with a significantly
decreased risk of developing cutaneous melanoma. 14
However, regular NSAID use may lead to serious side
effects encompassing the gastrointestinal, renal, and
cardiovascular systems.15–17 These potential life-threatening
side effects are limiting to the widespread use of NSAIDs
as potential chemopreventive agents.
Nitric-oxide-releasing NSAIDs (NO-NSAIDs) are
an emerging new class of chemopreventive agents. They
consist of a traditional NSAID attached to an NO-releasing
moiety through a chemical spacer. Animal18,19 and human20,21
studies have shown that many NO-NSAIDs are safer to the
gastrointestinal mucosa than the parent NSAID. We had
previously shown that an aromatic spacer enhanced the potency
of a particular NO-NSAID compared to an aliphatic spacer.22
At the cellular level, our previous studies have also demonstrated
that the chemopreventive effects may be mediated through
proapoptotic and antiproliferative effects of NO-NSAIDs in
various cancer cell lines of different cell types.23,24 Hence, for
these studies, we synthesized an NO-releasing arylpropionic
acid NSAID, comprising an aromatic spacer and evaluated it
against the human skin cancer cell line, A-431 which expresses
β-catenin. In this study, we compared the effects of the NSAID
flurbiprofen, NO-releasing-flurbiprofen containing an aliphatic
spacer, and the newly synthesized flurbiprofen benzyl nitrate
(FBN, NBS-242), which has an aromatic spacer on cell growth
inhibition. The effect of FBN on cell proliferation, apoptosis,
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and cell cycle was examined with a focus on the Wnt pathway
components.

Materials and methods
Reagents and cell culture
NO-flurbiprofen (4-(nitrooxy)butyl 2-(2-fluoro-[1,1′biphenyl]-4-yl)propanoate) and flurbiprofen benzyl
nitrate (4-O-[2-(3-fluoro-4-phenyl)phenyl propionyl]4-hydroxybenzyl nitrate, NBS-242) (Figure 1) were
synthesized and purified as described previously.25 Stock
solutions (100 mM) were made in dimethyl sulfoxide
(DMSO); the final DMSO concentration was adjusted in all
media to 1%. Flurbiprofen and other fine chemicals were
obtained from Sigma-Aldrich (St Louis, MO, USA). A-431
human epidermoid carcinoma (ATCC, Manassas, VA, USA)
cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
100 unit/mL of penicillin, and 100 µg/mL of streptomycin
in a humidified atmosphere containing 5% CO2 and 95%
air at 37°C.

Determination of cell viability
by MTT assay
Cell growth inhibition was measured using an MTT kit
(Roche, Indianapolis, IN, USA). A-431 cells were plated
at a density of 7000 cells/well in a 96-well plate. After
overnight incubation, cells were treated with vehicle or
various concentrations of the test compounds for 24 hours
after which viable cells were quantified according to the

Traditional NSAID

F

No-releasing
group

Spacer

H

O

C

C

CH2

ONO2

O

CH3

Flurbiprofen benzyl nitrate

F

H

O

C

C

CH3

(CH2)4

ONO2

O

NO-flurbiprofen
Figure 1 Structural features of flurbiprofen, NO-flurbiprofen, and flurbiprofen
benzyl nitrate.
Abbreviations: NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug.
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manufacturer’s instructions. Growth inhibition was expressed
as percentage of the corresponding control.

Proliferating cell nuclear antigen (PCNA)
staining for cell proliferation
A-431 cells (8000 cells/well) were treated for 24 hours
with various concentrations of FBN. Cell proliferation was
assessed by measuring the levels of PCNA using a PCNA
enzyme-linked immunosorbent assay kit (Calbiochem, La
Jolla, CA, USA), in accordance with the manufacturer’s
protocol.

4,6-diamidino-2-phenylindole (DAPI)
staining for cell death analysis
Chromatin condensation for detection of apoptosis was
determined by DAPI fluorescence. Cells were cultured in
the growth medium in the presence or absence of FBN for
24 hours. Cells were washed three times with phosphatebuffered solution (PBS), fixed in a 3.7% formaldehyde
solution for 10 minutes, fixed once in 1 mL of methanol,
stained, and mounted in a fluid containing 2 mg/mL
DAPI (Oncor Inc, Gaithersburg, MD, USA). Results were
determined by visual observation of nuclear morphology via
fluorescence microscopy.

Cell cycle analysis
A-431 cells were treated for 24 hours with various concentrations
of FBN. Cell cycle phase distributions of control and treated
cells were obtained using a Coulter Profile XL, (Beckman
Coulter, Inc., Fullerton, CA, USA) equipped with a single
argon ion laser. For each subset, .10,000 events were
analyzed. All parameters were collected in list mode files. Data
were analyzed on a Coulter XL Elite Workstation, (Beckman
Coulter, Inc.) using the software programs Multigraph and
Multicycle. Cells (0.5 × 106) were fixed in 100% methanol
for 10 minutes at −20°C, pelleted (5000 rpm for 10 minutes
at 4°C), resuspended, and incubated in PBS containing 1%
FBS/0.5% NP-40 on ice for 5 minutes. Cells were washed
again in 500 µL of PBS/1% FBS containing 40 µg/mL
propidium iodide (used to stain for DNA) and 200 µg/mL
RNase type IIA, and analyzed within 30 minutes by flow
cytometry. The percentage of cells in the G0/G1, G2/M, and S
phases was determined from DNA content histograms.

Cytoplasmic and nuclear protein
extraction
To obtain nuclear protein extracts, cell pellets were resuspended
in 500-µL lysis-buffer I (10 mM Tris-HCl [ph 7.4], 10 mM
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NaCl, 3 mM MgCl2, and 0.5% NP-40), incubated for 5 minutes
on ice, and centrifuged at 3200 rpm for 5 minutes. Nuclei were
then washed with washing buffer (10 mM Tris-HCl [pH 7.4],
10 mM NaCl, and 3 mM MgCl2), resuspended in lysis-buffer
II (20 mM Tris-HCl [pH 7.4], 40 mM Na-pyrophosphate,
50 mM NaF, 5 mM MgCl2, 20 mM ethylenediaminetetraacetic
acid [EDTA], 1% Triton-X-100, and 0.5% SDS, 0.1 mM
phenylmethylsulfonyl fluoride [PMSF]), sonicated, and
centrifuged at 14,000 rpm for 10 minutes. The supernatant
was diluted by the addition of one vol lysis buffer III (20 mM
HEPES-KOH, pH 7.4, 0.2 mM EDTA, 0.5 mM PMSF, and
2 mM dithiothreitol). Glycerol was added to obtain a final
concentration of 20%, and aliquots were stored at −80°C.
Lastly, 50 µg of soluble extracts and 30 µg of nuclear extracts
were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) followed by immunoblotting
according to standard protocols.

Antibodies
Primary mouse monoclonal antibodies were against the following
at the dilutions indicated: β-catenin, 1:1000 (BD Transduction
Laboratories, San Jose, CA, USA); TCF-4, 1:500 (Upstate
Biotechnology, Lake Placid, NY, USA); α-tubulin, 1:1000
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); Cox-2,
1:2000 (Cayman Chemicals, Ann Arbor, MI, USA), and rabbit
polyclonal anti-cyclin D1, 1:1000 (Upstate Biotechnology).
Secondary antibodies conjugated to horseradish peroxidase
(1:4000) were from Sigma-Aldrich. Immunoreactive protein
was detected by using chemiluminescence (Pierce Chemicals,
Rockford, IL, USA).

Statistics

Data are presented as the mean ± standard error of the mean,
with sample sizes as indicated in figure legends. Comparisons
between groups were performed using a one-way analysis
of variance followed by a Student’s t-test; P , 0.05 was
considered significant.

Results
FBN strongly inhibits the growth
of A-431 cells
We examined the growth inhibitory activities of FBN,
NO-flurbiprofen, and flurbiprofen (their structures are
presented in Figure 1) by an MTT assay in the A-431 human
epidermoid carcinoma cell line. For the initial growth
inhibition study, a wide range of doses of the three compounds,
including up to 1000 µM for flurbiprofen, were used in
order to obtain observable readouts for all the compounds.
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After treatment of cells for 24 hours, the percent inhibition
was determined for the various concentrations examined.
Overall, all three compounds inhibited cell growth in
a concentration-dependent manner. Among the three
compounds, flurbiprofen exhibited a moderate inhibitory
effect on cell growth, the aliphatic NO-flurbiprofen strongly
inhibited growth, whereas the aromatic NO-flurbiprofen
(FBN) was significantly more potent (Figure 2). The half
maximal inhibitory concentration (IC50) values determined
for each compound were 880 ± 65 µM, 320 ± 20 µM, and
60 ± 4 µM for flurbiprofen, aliphatic NO-flurbiprofen, and
FBN, respectively. The ratio of the IC50s (traditional NSAID/
modified NSAID), which reflects the fold increase in potency,
indicated that FBN was 15-fold more potent than flurbiprofen
and up to 5-fold more potent than NO-flurbiprofen. A lower
IC50 of FBN compared to NO-flurbiprofen in A-431 cells
strongly suggests that the aromatic spacer may contribute
to the strong growth suppressive properties of FBN either
alone or by modifying delivery of NO. For further studies
we focused on the effects of FBN on cellular kinetics such
as proliferation, apoptosis, and cell cycle.

FBN affects proliferation
and induces apoptosis

Cell growth inhibition, % control

Proliferation and apoptosis are two major parameters
determining cellular mass. We examined the effects of FBN

FBN (NBS-242)
No-flurbiprofen
Flurbiprofen

100

IC50 = 60 ± 4 µM§,†

80

IC50 = 320 ± 20 µM*

60
IC50= 880 ± 65 µM
40

20

0
1

10

100

1000

10,000

Drug concentration, µM
Figure 2 Inhibitory effect of FBN on A-431 cell growth.
Notes: Cells were treated with increasing concentrations of flurbiprofen, NO
flurbiprofen, and FBN for 24 hours. Cell viability was determined by MTT assay as
described in the Materials and methods section. Results are means ± SEM of three
different experiments performed in triplicate. *P , 0.05 compared to flurbiprofen;
†
P , 0.01 compared to flurbiprofen; §P , 0.05 compared to NO-flurbiprofen.
Abbreviations: FBN, flurbiprofen benzyl nitrate; IC50, half maximal inhibitory
concentration; NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug;
SEM, standard error of the mean.
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after 24 hours of treatment on these two parameters. PCNA
is an index of the proliferative status of cells. FBN caused a
concentration-dependent reduction of PCNA in A-431 cells
from 10 to 75 µM (Figure 3A). Compared to the control,
the maximal antiproliferative activity of FBN was 15%
at 75 µM and remained relatively constant for increasing
concentrations, suggesting that inhibition of proliferation
may be a partial contributor to the growth inhibitory effect
of FBN. On the other hand, the percentage of apoptotic cells,
as measured by counting DAPI stained nuclei with apoptotic
morphology, increased in a concentration dependent
manner from 10 to 100 µM FBN. At 75 µM, approximately
50% of the cells were apoptotic compared to the control
(Figure 3A).
Since the induction of apoptosis may be mediated through
the regulation of cell cycle, we examined the effect of FBN
on cell cycle perturbations (Figure 3B). Cells were treated
with various concentrations of FBN for 24 hours and their
DNA content, as assessed by flow cytometric analysis,
indicated that FBN-treated cells progressively accumulated
in the G0/G1 phase; for example, at 100 µM compared to
untreated cells, the proportion of cells in the G0/G1 phase
increased from 61% to 73%, and concomitantly decreased
the proportion of cells in the G2/M phase from 21% to 9%.
Collectively, our data indicate that FBN induces cell cycle
arrest and apoptosis in A-431 cells.

FBN targets components of the Wnt
pathway and induces caspase-3

According to the canonical Wnt/β-catenin pathway, β-catenin
translocates to the nucleus, interacting with TCF and
modulating transcription of specific genes. We examined the
effect of FBN on β-catenin protein levels in the cytoplasm
and nucleus in these cells. FBN cleaved cytoplasmic and
nuclear β-catenin as a function of concentration (Figure 4A
and B), with substantial degradation at 75 µM and 100 µM.
In the cytoplasm, the functional consequence of reduced
levels of β-catenin cleavage was examined by determining
the cytoplasmic protein expression of cyclin D1. Cyclin D1
represents an early G1 phase cyclin and is a consequence
of β-catenin/TCF-4 transcriptional activity. FBN at 25 µM
reduced cytoplasmic cyclin D1 levels and abrogated its
expression completely at 75 µM (Figure 4A). This abrogation
was associated with β-catenin degradation observed at these
concentrations. On the other hand, nuclear expression of cyclin
D1, which is a result of protein export from the cytoplasm to
the nucleus, was also strongly reduced (Figure 4B). Since these
cells were asynchronously dividing, it is understandable that at

Drug Design, Development and Therapy 2013:7

Dovepress

NBS-242 inhibits A-431 cell growth and targets β-catenin

B

A
Proliferation, PCNA

†

†

60
†

40

*

20

0

G2/M

*

80
S

*

*

60

40

20

G0/G1

*

80

% positive

100

Apoptosis, DAPI

Percent cell distribution

100

0
0

10

50

75

100

200

0

[FBN], µM

10

50

100

200

[FBN], µM

Figure 3 Effect of FBN on cell kinetics. FBN causes G0/G1 cell cycle arrest, induces apoptosis, and inhibits proliferation. (A) A-431 cells were treated with FBN at the
indicated concentrations for 24 hours followed by PCNA quantification for proliferation or DAPI staining of apoptotic nuclei and counting as described in the Materials and
methods section. Results are mean ± SEM of three different experiments. *P , 0.05; †P , 0.01 compared with untreated cells. (B) Asynchronous A-431 cells were treated
with increasing concentrations of FBN as indicated for 24 hours.
Notes: The cells were then harvested and the percentage of the cells in the G0/G1, S, and G2/M phases were analyzed by flow cytometry. The populations of the cells (G0/G1,
S, and G2/M phases) are expressed as a percentage of the total cell population. Data shown here are from a representative experiment repeated two times with similar
results, within 10% of each other.
Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; FBN, flurbiprofen benzyl nitrate; PCNA, proliferating cell nuclear antigen; SEM, standard error of the mean.

any time of treatment with FBN cytoplasmic cyclin D1 and its
nuclear levels will be affected. We further examined the protein
level of TCF-4, the transcription factor in the nucleus that binds
to β-catenin. FBN completely reduced the expression of TCF-4
at 75 µM. Thus, FBN targets the two major elements of the Wnt
pathway, namely β-catenin and TCF-4. Our data demonstrate
that FBN induces G1 cell cycle arrest, which agrees well with
the marked downregulation of cyclin D1.
We also examined the activation of caspases by
FBN since there was a strong induction of apoptosis in
A-431 cells by DAPI staining as shown in Figure 3A.
Caspase activation constitutes the hallmark of apoptotic
detection and it is well known that β-catenin is a direct
target of caspase-3 activity. 24 Therefore, the activation
of caspase-3 was examined in the cytoplasm fraction of
A-431 cells by performing immunoblotting detection for
procaspase-3 and its smaller cleaved fragment, signifying
the activation of caspase-3. The appearance of activated
caspase-3 was observed initially at 50 µM FBN, followed
by a substantial increase in activation at 75 and 100 µM
FBN, with simultaneous reduction in levels of procaspase-3
(Figure 4A). The activation of caspase-3 coincided with the
cleavage of β-catenin at 50 and 75 µM suggesting that there
is an association between the events.

Drug Design, Development and Therapy 2013:7

Discussion
This study demonstrates the potential of the aromatic
NO-releasing compound FBN against skin cancer of the
nonmelanocytic type that is known to occur via constitutive
activation of β-catenin/TCF signaling. We report, for the first
time, the effects of an NO-releasing flurbiprofen that has an
aromatic spacer. FBN is more potent than NO-flurbiprofen
and flurbiprofen in inhibiting the growth of the A-431 skin
cancer cell line.
The data suggest a possible link between the growth
inhibitory effects of FBN and the β-catenin pathway as a
potential target. Studies in recent years have suggested that
β-catenin accumulation has been implicated in tumorigenesis
in a wide variety of human cancers including skin cancer.3
These studies suggest, in essence, that degrading nuclear
accumulation of β-catenin suppresses tumorigenesis. Our data
show the possible molecular mechanism underlying the antigrowth effect of FBN. Taken together, these results suggest that
the reduction of β-catenin expression by FBN may contribute
to an antiproliferative mechanism in A-431 skin cancer
cells. Others have shown that downregulation of β-catenin
expression by accelerating its proteasomal degradation led
to impaired cell proliferation and abolished the tumorigenic
potential of these cells in the nude mice model.26 In this
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Figure 4 FBN degrades β-catenin, inhibits cyclin D1, and activates caspase-3.
Notes: A-431 cells were treated with FBN at the indicated concentrations for 24 hours followed by cytoplasmic and nuclear protein extraction. Proteins were detected by
immunoblotting with specific antibodies. Results are representative of two independent experiments. The densitometry of the bands was within 15% of each other.
Abbreviations: FBN, flurbiprofen benzyl nitrate; TCF, T-cell factor.

regard, the NSAID R-flurbiprofen was reported to show strong
antiproliferative effects in vivo and in vitro.27 However, very
high concentrations of this compound, such as 1000 µM
R-flurbiprofen, did not affect the protein level of β-catenin or
induce its degradation.27 An interesting future goal would be to
determine whether proteolytic cleavage of β-catenin is simply
an effect of apoptosis or induces the apoptotic program. The
versatile functions of β-catenin within the interplay of cell
growth and cell death will be an interesting aspect for future
studies on FBN.
Since the only difference between NO-flurbiprofen and
FBN is the linker joining the NO-releasing group to the
NSAID flurbiprofen, it may be concluded that the enhanced
potency observed with FBN may be due to the aromatic linker
alone, or the way in which NO is delivered or a combination
of both.
Previous work by us on the structure–activity properties of
NO-aspirin had indicated that NO was pivotal for its anticancer
effects.22 However, careful re-examination regarding the
contribution to the overall biological effect of each of the
three structural components of NO- acetylsalicylate (ASA)
in which the spacer joining the ASA to the NO-releasing
moiety was aromatic, led us and others to conclude that
the NO-releasing moiety was not required for the observed
biological effects. Rather, the spacer was responsible for
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the biological actions of NO-aspirin, with the NO-releasing
moiety acting as a leaving group that facilitated the release
and activation of the spacer to a quinone methide intermediate
which acted as a powerful electrophile.28–30 Here, we have
NO-flurbiprofen which was ∼2.8-fold more potent than its
parent compound flurbiprofen in inhibiting the growth of
A-431 cells and FBN which was ∼15-fold more potent. On
this basis, we may cautiously conclude that with FBN we may
have two effects, one as a result of released NO and one due
to an active aromatic linker.
Finally, FBN is able to reduce PCNA levels, which is
a polymerase accessory protein detected in a cell-cycledependent manner,31 with a marked downregulation of cyclin
D1. The cyclin D1 proto-oncogene is an important regulator
of G1 to S phase transition in numerous cell types from diverse
tissues. This series of events results in a G1 phase arrest of
the cell cycle, which is an irreversible process that ultimately
results in the apoptotic death of cancer cells.
In conclusion our data establish a strong inhibitory
effect of FBN in A-431 human epidermoid carcinoma cells,
an effect that is modulated through parameters important
in determining cellular mass. FBN is more potent than
NO-flurbiprofen and flurbiprofen in the inhibition of cell
proliferation. Activation of caspase-3 is associated with
degradation of β-catenin and reduction in cyclin D1 levels,
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suggesting that FBN has potential as a chemotherapeutic
agent against NMSC.
Two major aspects constitute future directions for this study.
First, at the mechanistic level, the degradation of β-catenin by
FBN merits further investigation regarding the sequence of events
in relation to caspase activity. A second focus is the potential
of FBN in topical treatment regimens, which are generally
considered to be better alternatives for nonmelanoma skin
cancer in minimizing systemic exposure while achieving high
local concentrations of the drug. We are currently formulating
hydrogel-delivering systems for local application of FBN.
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